Company Interview / The small cap taking on a big fight

Key points:

Invion targets non-melanoma skin cancer with novel photodynamic therapy Combination treatments improve prostate cancer trial response to 80%Company's cost-effective approach boosts market excitement with shares up over 100%

Thian Chew of Invion (ASX: IVX) is focusing on photodynamic therapy to develop effective and affordable treatments for cancers, particularly non-melanoma skin cancer. The latest trial in Sydney aims to address the high occurrence of skin cancer in Australians without causing severe scarring.

Thian states photodynamic therapy activates compounds in cancer cells, sparing healthy tissue and triggering an immune response. Invion's trials show promising results in prostate cancer, with 40-44% response rates and combination treatments increasing response rates to 80%.

Invion's small molecule approach allows scalability, offering a more affordable cancer treatment. Thian aims to expand trials internationally, ensuring broader accessibility. The company's shares have risen by over 100%, signalling market excitement.